Author(s):
Maram Bilal, Jumana Al-Saleh, Faihaa Abo Fakher
Email(s):
maramybilal86@gmail.com
DOI:
10.5958/0974-360X.2021.00058.5 
Address:
Maram Bilal1*, Jumana Al-Saleh2, Faihaa Abo Fakher3
1Department of Biochemistry and Microbiology, Faculty of Pharmacy, Damascus University, Damascus, Syria.
2Assisstant Professor, Department of Biochemistry and Microbiology, Faculty of Pharmacy, Damascus University, Damascus, Syria.
3Associate Professor, Department of Laboratory Medicine, Faculty of Medicine, Damascus University, Damascus, Syria.
*Corresponding Author
Published In:
Volume - 14,
Issue - 1,
Year - 2021
ABSTRACT:
Background: The link between chronic inflammation and tumorogenesis has been noted for a long time. Breast tumor cell-derived prostaglandin E2 (PGE2) induces the production of interleukin 23 (IL-23) that enhances IL-17 secretion. Permanent release of these molecules leads to augmentation of their serum concentrations that may be used as novel clinical markers for diagnosis and prognosis. The aim of this research was to evaluate levels of IL-17 and PGE2 in blood serum of breast cancer patients, and to determine whether these levels correlate with the disease progression Material and Methods: Pre-operative serum samples were collected from 41 patients with breast cancer and 28 patients with benign breast tumors. IL-17 and PGE2 levels were measured using ELISA. Furthermore, correlations between levels of these molecules and clinicopathological parameters were determined. Results: We demonstrated that serum levels of PGE2, but not IL-17, were significantly increased in breast cancer patients as compared with benign tumor patients. Moreover, both IL-17 and PGE2 levels were increased in cancer patients with angiogenesis and lymph node metastasis. A positive correlation was also identified between IL-17 and PGE2 levels. Conclusion: The present study indicates that elevated IL-17 and PGE2 serum concentrations are associated with angiogenesis and metastasis of breast cancer. So, our data suggest that IL-17 and PGE2 could be developed as potential biomarkers of breast cancer diagnosis and prognosis, however more comprehensive results are needed.
Cite this article:
Maram Bilal, Jumana Al-Saleh, Faihaa Abo Fakher. Serum levels of prostaglandin E2 (PGE2) and interleukin 17 (IL-17) are associated with Angiogenesis and Metastasis in breast cancer patients. Research J. Pharm. and Tech. 2021; 14(1):317-320. doi: 10.5958/0974-360X.2021.00058.5
Cite(Electronic):
Maram Bilal, Jumana Al-Saleh, Faihaa Abo Fakher. Serum levels of prostaglandin E2 (PGE2) and interleukin 17 (IL-17) are associated with Angiogenesis and Metastasis in breast cancer patients. Research J. Pharm. and Tech. 2021; 14(1):317-320. doi: 10.5958/0974-360X.2021.00058.5 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-1-58
REFERENCES:
1- Scully O, Bay B, Yip G and Yu Y. Breast Cancer Metastasis. Cancer Genomics and Proteomics 2012; 9(5): 311-320.
2- De Nardo DG and Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007; 9:212-222.
3- Howe L. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Research 2007; 9(4):210-218.
4- Qian X, Gu L, Ning H, Zhang Y, Hsueh E, Fu M, Hu X, Wei L, Hoft D and Liu J. Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2. J Immunol. 2013; 190(11):5894–5902.
5- Gaffen S. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009; 9(8):556–567.
6- Murugaiyan G and Saha B. Protumor vs antitumor functions of IL-17. J. Immunol. 2009; 183(7):4169-4175.
7- Numasaki M, Fukushi J, Ono M, Narula S, Zavodny P, Kudo T, Robbins P, Tahara H and Lotze M. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101(7):2620–2627.
8- Yang B, Kang H, Fung A, Zhao H, Wang T and Ma D. The Role of Interleukin 17 in Tumour Proliferation, Angiogenesis, and Metastasis. Mediators of Inflammation 2014:1-11.
9- Rohani Borj M, Andalib AR, Mohammadi A, Hoseiniharouni S, Pourghadamyari H, Azizi H, Golmohammadi T and Ghahfarokhy K. Evaluation of IL-4, IL-17, and IFN-γ levels in patients with breast cancer. Int J Basic Sci Med. 2017; 2(1):20-24.
10- Lyon D, McCain N, Walter J and Schubert C. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs. Res. 2008; 57:51–58.
11- Mettler L, Salmassi A, Heyer M, Schmutzier A, Schollmeyer T, Jonat W. Perioperative levels of interleukin-1 beta and interleukin-6 in women with breast cancer. Clinical and Experimental Obstetrics & Gynecology 2004; 31(1):20–22.
12- Mitsuhashi M, Liu J, Cao S, Shi X and Ma X. Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. J Leukoc Biol. 2004; 76:322–332.
13- Kumara S, Jang J, Herath S, Kirchoff D, Yan X, Cekic V and Whelan R. Plasma Levels of Prostaglandin E2 (PGE2), A Protein With Proangiogenic Effects, Are Elevated in Colorectal Cancer Patients. Gastroenterology 2011; 140(5): 685-687.
14- Dong C. Mouse Th17 cells: current understanding of their generation and regulation. Eur. J. Immunol. 2009; 39(3):640–644.
15- Langrish C, Chen Y, Blumenschein W, Mattson J, Basham B, Sedgwick J, McClanahan T, Kastelein R and Cua D. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. JEM. 2005; 201(2):233–240.
16- Benevides L, Cardoso C, Tiezzi D, Marana H, Andrade J and Silva J. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur. J. Immunol. 2013; 43(6):1518–1528.
17- Benevides L, da Fonseca DM, Donate PB, Tiezzi DG, De Carvalho DD, de Andrade JM, Martins GA, Silva JS. IL17 Promotes Mammary Tumor Progression by Changing the Behavior of Tumor Cells and Eliciting Tumorigenic Neutrophils Recruitment. Cancer Res. 2015; 75(18):3788-99.
18- Timoshenko AV, Xu G, Chakrabarti S, Lala PK and Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res. 2003; 289:265–74.
19- Buchanan FG, Wang D, Bargiacchi F and DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003; 278:35451–7.
20- Amano H, Ito Y, Suzuki T, Kato S and Matsui Y. Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis. Cancer Sci. 2009; 100(12):2318–2324.
21- Chang S, Liu C, Conway R, Han D, Nithipatikom K, Trifan O, Lane T and Hla T. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci. 2004; 101:591-596.
22- Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, Kobayashi M, Satoh K, Narita M, Sugimoto Y, Murata T, Yoshimura H, Narumiya S and Majima M. Host Prostaglandin E2-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth. J. Exp. Med. 2003; 197(2):221-232.